A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants

MedImmune

Status and phase

Withdrawn

Phase 3

Conditions

Wheezing

Treatments

Biological: Motavizumab

Other: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT00628303

MI-CP169

Details and patient eligibility

About

The primary objective of this study is to assess the efficacy of motavizumab compared to placebo when administered monthly to preterm infants during their first RSV season for the reduction of the incidence of serious early childhood wheezing from their 2nd through 3rd birthdays.

Full description

The primary objective of this study is assess the efficacy of motavizumab compared to placebo when administered monthly by intramuscular (IM) injection during the first RSV season for the reduction of the incidence of serious early childhood wheezing in preterm infants between their 2nd and 3rd birthdays.

Sex

All

Ages

Under 6 months old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Male or female infants born at 32 & 1/7 - 35 & 0/7 weeks GA, determined according to available medical records
Chronological age of <6 months of age at randomization
In good health, in the opinion of the investigator
Not more than one of the following AAP-defined risk factors:
1. Childcare attendance
2. School-aged siblings
3. Exposure to environmental air pollutants (not including passive exposure to tobacco smoke)
Ability and willingness of the subject's parent/legal guardian to complete all protocol-mandated follow-up telephone contacts, visits and procedures
Written informed consent obtained from the subject's parent(s) or legal guardian

Exclusion criteria

Diagnosis of CLD of prematurity (also referred to as BPD) or other chronic pulmonary diseases
Diagnosis of hemodynamically significant CHD, defined as requiring medication or supplemental oxygen for their CHD
Congenital abnormalities of the airways
Severe neuromuscular disease, as determined by the investigator
Previous or concurrent treatment with palivizumab or intravenous immunoglobulin (IVIG)
Eligible for prophylaxis based on local medical standards and guidelines at participating sites
Known immunodeficiency
Previous or current diagnosis of an upper or lower respiratory infection by a medical professional
Previous or current diagnosis of wheezing, asthma, or other wheezing-related diagnoses
Hospitalization at the time of enrollment (in case admitted to nursery as part of routine care, infant should only be randomized immediately prior to being discharged)
Any illness or condition that would preclude long-term survival
Participation in a trial or an investigational agent for RSV prophylaxis or therapy
Inability to be followed through their 3rd birthday